Landos Biopharma, Inc, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, and LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, today announced an exclusive collaboration and license agreement for the development and commercialization of omilancor and NX-13 …

Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, announced that the Company has dosed the first patient in a Phase 2 study of omilancor, Landos’ novel, orally administered, gut-restricted LANCL2 agonist, for the treatment of moderate-to-severe Crohn’s disease (CD). “We are extremely proud of …

BIO-CAT, Inc., a biotechnology company that specializes in enzymes and other advanced microbial solutions, plans to add at least 30,000 square feet to its fermentation facilities in Zion Crossroads. The expansion is projected to start in 2022. The company will add several new jobs and is considering building another 30,000-square-foot section in a second phase. …

Contraline, Inc., a venture-backed medical device company devoted to providing men and couples with long-lasting, safe, and effective male contraception, has appointed medical device industry executive Martin Emerson to its Board of Directors.

AMPAC Fine Chemicals announced a $25 million expansion of its operations that is expected to add more than 150 new jobs. The California-based company is a top U.S. manufacturer of active pharmaceutical ingredients. The plant in Petersburg previously was owned by Boehringer Ingelheim Chemicals Inc., which closed it in 2014, but AMPAC reopened the site …

ivWatch, LLC has been awarded a group purchasing agreement for Patient Safety Solutions with Premier, Inc. to provide more than 4,000 Premier member hospitals with greater access to the only continuous peripheral IV (PIV) site monitoring technology available in the market. The three-year agreement underscores the importance of detecting IV infiltration and extravasation events early …